Hydroxychloroquine in lupus erythematosus, a new horizon of the old drug
Trends in Immunotherapy · 2017
DOI: 10.24294/ti.v1.i3.127 ↗Kurz gefasst
Fachartikel in der Zeitschrift Trends in Immunotherapy, 2017. Verfasst von Fukumi Furukawa. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
COPYRIGHT Copyright © 2017 by author(s) and EnPress Publisher LLC. This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). http://creativecommons.org/licenses/by/4.0/ In this volume 1 issue 3, Japanese doctors present a discoid lupus erythematosus (DLE) patient well treated with hydroxychloroquine (HCQ) (Figure 1), in whom urticarial reaction was transiently worsened. This case has two underlying aspects especially for Japanese doctors, which is probably shared with Asian doctors. production was discontinued in 1974 because of lawsuits brought by patients who developed retinopathy.
Zitieren
APA
Furukawa, F. (2017). Hydroxychloroquine in lupus erythematosus, a new horizon of the old drug. Trends in Immunotherapy. https://doi.org/10.24294/ti.v1.i3.127
Vancouver
Furukawa F. Hydroxychloroquine in lupus erythematosus, a new horizon of the old drug. Trends in Immunotherapy. 2017. doi:10.24294/ti.v1.i3.127
BibTeX
@article{Furukawa2017,
author = {Furukawa, Fukumi},
title = {Hydroxychloroquine in lupus erythematosus, a new horizon of the old drug},
journal = {Trends in Immunotherapy},
year = {2017},
doi = {10.24294/ti.v1.i3.127}
}
EUVIMED